Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles

被引:62
作者
Porrello, Enzo R. [1 ,2 ]
Pfleger, Kevin D. G. [4 ,5 ,6 ]
Seeber, Ruth M. [4 ,5 ]
Qian, Hongwei [2 ]
Oro, Cristina [2 ]
Abogadie, Fe [1 ]
Delbridge, Lea M. D. [1 ]
Thomas, Walter G. [2 ,3 ]
机构
[1] Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia
[2] Baker IDI Heart & Diabet Inst, Melbourne, Vic 8008, Australia
[3] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia
[4] Univ Western Australia, Lab Mol Endocrinol GPCRs, Western Australian Inst Med Res, Perth, WA 6009, Australia
[5] Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia
[6] Dimerix Biosci Pty Ltd, Perth, WA 6009, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会;
关键词
AT(1) receptor; AT(2) receptor; Homomerization; Heteromerization; Protein-fragment complementation assay; GPCR-HIT; PROTEIN-COUPLED RECEPTORS; ENERGY-TRANSFER BRET; II TYPE-1 RECEPTOR; AT2; RECEPTOR; BETA-ARRESTIN; DRUG TARGETS; OLIGOMERIZATION; INTERNALIZATION; LIGAND; CELLS;
D O I
10.1016/j.cellsig.2011.06.011
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The cardiovascular hormone angiotensin II (AngII) exerts its actions via two G protein-coupled receptor (GPCR) subtypes, AT(1) and AT(2), which often display antagonistic functions. Methodological constraints have so far precluded detailed analyses of the ligand-dependency, cellular localization, and functional relevance of AngII receptor interactions in live cells. In this study, we utilize a protein-fragment complementation assay (PCA) and GPCR-Heteromer Identification Technology (GPCR-HIT) to provide the first detailed investigation of the ligand-dependency and cellular localization of AngII receptor interactions in human embryonic kidney 293 cells. Fluorescent-tagged receptor constructs for PCA and GPCR-HIT displayed normal affinity and selectivity for AngII (AT(1): IC50 = 1.0-1.6 nM; AT(2): IC50 = 2.0-3.0 nM). Well-characterized angiotensin receptor interactions were used as positive and negative controls to demonstrate the sensitivity and specificity of these fluorescence-based assays. We report that AT(1)-AT(2) receptor heteromers form constitutively, are localized to the plasma membrane and perinuclear compartments, and do not internalize following AngII stimulation despite arrestin being recruited specifically to the heteromer. Our findings using novel fluorescence-based technologies reveal a previously unrecognized mechanism of angiotensin receptor cross-talk involving cross-inhibition of AT(1) receptor internalization through heteromerization with the AT(2) receptor subtype. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1767 / 1776
页数:10
相关论文
共 45 条
[1]   The angiotensin II AT2 receptor is an AT1 receptor antagonist [J].
AbdAlla, S ;
Lother, H ;
Abdel-tawab, AM ;
Quitterer, U .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (43) :39721-39726
[2]  
[Anonymous], 2010, Drug Discov Today Technol, V7, pe1, DOI 10.1016/j.ddtec.2010.06.003
[3]   Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization [J].
Ayoub, Mohammed A. ;
Pfleger, Kevin D. G. .
CURRENT OPINION IN PHARMACOLOGY, 2010, 10 (01) :44-52
[4]   Hetero-oligomerization between β2-and β3-adrenergic receptors generates a β-adrenergic signaling unit with distinct functional properties [J].
Breit, A ;
Lagacé, M ;
Bouvier, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (27) :28756-28765
[5]   The Angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor - Mediated hypertrophy [J].
D'Amore, A ;
Black, MJ ;
Thomas, WG .
HYPERTENSION, 2005, 46 (06) :1347-1354
[6]   G protein-coupled receptor dimers: Functional consequences, disease states and drug targets [J].
Dalrymple, Matthew B. ;
Pfleger, Kevin D. G. ;
Eidne, Karin A. .
PHARMACOLOGY & THERAPEUTICS, 2008, 118 (03) :359-371
[7]  
de Gasparo M, 2000, PHARMACOL REV, V52, P415
[8]   Helix I of β-arrestin is involved in postendocytic trafficking but is not required for membrane translocation, receptor binding, and internalization [J].
Dinh, DT ;
Qian, HW ;
Seeber, R ;
Lim, E ;
Pfleger, K ;
Eidne, KA ;
Thomas, WG .
MOLECULAR PHARMACOLOGY, 2005, 67 (02) :375-382
[9]  
Dromey Jasmin R., 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P51, DOI 10.2174/187153008783928352
[10]   Building a new conceptual framework for receptor heteromers [J].
Ferre, Sergi ;
Baler, Ruben ;
Bouvier, Michel ;
Caron, Marc G. ;
Devi, Lakshmi A. ;
Durroux, Thierry ;
Fuxe, Kjell ;
George, Susan R. ;
Javitch, Jonathan A. ;
Lohse, Martin J. ;
Mackie, Ken ;
Milligan, Graeme ;
Pfleger, Kevin D. G. ;
Pin, Jean-Philippe ;
Volkow, Nora D. ;
Waldhoer, Maria ;
Woods, Amina S. ;
Franco, Rafael .
NATURE CHEMICAL BIOLOGY, 2009, 5 (03) :131-134